Skip to main content
SpringerLink
Log in

Rufinamide: a guide to its use in Lennox-Gastaut syndrome

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Hancock EC, Cross HJ. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2009; (3): CD003277

    PubMed  Google Scholar 

  2. van Rijckevorsel K. Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat 2008 Dec; 4(6): 1001–19

    Article  PubMed  Google Scholar 

  3. Perucca E, Cloyd J, Critchley D, et al. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008; 49(7): 1123–41

    Article  PubMed  CAS  Google Scholar 

  4. European Medicines Agency. Inovelon: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu [Accessed 2010 Mar 24]

  5. Marchand M, Fuseau E, Critchley DJ. Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial simulation. J Pharmacokinet Pharmacodyn 2010 Feb; 37(1): 99–118

    Article  PubMed  CAS  Google Scholar 

  6. Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008 May 20; 70(21): 1950–8

    Article  PubMed  CAS  Google Scholar 

  7. Glauser T, Kluger G, Sachdeo R, et al. Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome [abstract no. p1356]. Epilepsia 2005; 46Suppl. 6: 408

    Google Scholar 

  8. Wheless JW, Conry J, Krauss G, et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009; 24(12): 1520–5

    Article  PubMed  Google Scholar 

  9. Kluger G, Kurlemann G, Haberlandt E, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav 2009; 15(3): 491–5

    Article  Google Scholar 

  10. European Medicines Agency. Lamictil: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu [Accessed 2010 Mar 24]

  11. European Medicines Agency. Topamax: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu [Accessed 2010 Mar 24]

  12. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999; 21(6): 489–501

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rufinamide: a guide to its use in Lennox-Gastaut syndrome. Drugs Ther. Perspect 26, 6–9 (2010). https://doi.org/10.2165/11205230-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11205230-000000000-00000

Search

Navigation